MAPKs (ERK1/2 and p38) are modulated in a receptor and cell-specific manner. Whole cell lysates obtained from MCF-7, MDA-MB231 and T47D cells following treatment with SSTR2 and ORs agonists alone and/or in combination were subjected to western blot analysis and probed for phospho-and total ERK1/2 and p38 (1:1000). (A) Immunoblots illustrating agonist mediated changes in phosphorylated ERK1/2 in cell-specific manner. (B) Immunoblots displaying changes in the phosphorylation of p38 upon specific agonist treatments in breast cancer cells. SSTR2 and ORs activation inhibited p38 phosphorylation upon indicated treatment. Histograms depict changes in the expression levels of ERK1/2 using densitometric analysis. The data presented here is a representation mean ± SEM of three independent experiments. Significant difference was considered at *p < 0.05 vs. control.